Ziprasidone

This classification denotes an antipsychotic agent with the molecular formula C21H21ClN4OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6UKA5VEJ6X, chemically known as 2h-indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro- but generally known as ziprasidone, which bears US NIH Compound Identifier 60854. European Medicines Agency schedules Ziprasidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00168MIG. The term ZIPRASIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). World Health Organization schedules ziprasidone in its Anatomical Therapeutic Chemical (ATC) Classification. ZIPRASIDONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ziprasidone under HS 29341000 and SITC 51579. As of Q4 2014, ZIPRASIDONE remains the US FDA Preferred Term for this commodity. Ziprasidone bears US NLM identifiers UMLS ID C0380393 and NCI Concept Code C47788. SMILES: CLC1C(CCN2CCN(CC2)C2NSC3C2CCCC3)CC2C(NC(=O)C2)C1.